SL Science is a pre-clinical stage biomedical company developing cellular and gene therapies for blood cancers and solid tumors, including pancreatic and brain cancer. The company uses two proprietary platforms: CD-19 Armed-T Therapy, which employs bispecific antibodies to direct immune cells without genetic modification, and Gamma Delta T (GDT) Cell Therapy, an off-the-shelf approach designed to attack tumors that evade conventional immune recognition. All oncology candidates remain in pre-clinical development, with IND filings targeted for 2027. SL Science operates a license-in, develop, and license-out business model, licensing core technologies from CytoArm and JY BioMed. The company plans to fund early-stage development before seeking partnerships or acquisitions by large pharmaceutical firms during clinical trials to transfer the costs and risks of commercialization. While its biotech programs progress, SL Science generates revenue through a legacy consumer products business in Taiwan that sells exosome-based skincare and hair care products. Management views this consumer segment as non-core and intends to phase it out as the cell therapy pipeline matures.